Description: Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we've partnered with and educated governments, policy makers, payers, and heathcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We've also worked diligently and strategically to identify and address the unmet treatment needs of patients. By creating a marketplace environment of increased acceptance, we have provided an estimated 5 million patients effective treatment options.
Home Page: www.indivior.com
10710 Midlothian Turnpike
North Chesterfield,
VA
23235
United States
Phone:
804 379 1090
Officers
| Name | Title |
|---|---|
| Mr. Mark Crossley | CEO & Exec. Director |
| Mr. Ryan Preblick | CFO & Exec. Director |
| Dr. Christian Heidbreder | Chief Scientific Officer |
| Mr. Jason Thompson | VP of Investor Relations |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer |
| Mr. Jeffrey W. Burris | Chief Legal Officer |
| Mr. Jon Fogle | Chief HR Officer |
| Mr. Richard Simkin | Chief Commercial & Strategy Officer |
| Mr. Hillel West | Chief Manufacturing & Supply Officer |
| Ms. Nina DeLorenzo | Chief Global Impact Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.2414 |
| Price-to-Sales TTM: | 3.4096 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1000 |